Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Voyager Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Voyager Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$120.57M. For fiscal 2025 it was -$132.47M. The highest annual figure on record is $77.92M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.47M | – |
| FY2024 | Dec 31, 2024 | -$15.31M | -119.6% |
| FY2023 | Dec 31, 2023 | $77.92M | – |
| FY2022 | Dec 31, 2022 | -$12.51M | – |
| FY2021 | Dec 31, 2021 | -$53.53M | – |
| FY2020 | Dec 31, 2020 | -$96.72M | -298.7% |
| FY2019 | Dec 31, 2019 | $48.67M | – |
| FY2018 | Dec 31, 2018 | -$15.89M | – |
| FY2017 | Dec 31, 2017 | -$61.35M | – |
| FY2016 | Dec 31, 2016 | -$42.48M | -202.9% |
| FY2015 | Dec 31, 2015 | $41.30M | – |
| FY2014 | Dec 31, 2014 | -$11.92M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.90M | -164.5% |
| Q4 FY2024 | Dec 31, 2024 | -$14.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$31.58M | – |
| Q1 FY2024 | Mar 31, 2024 | $58.77M | -52.4% |
| Q4 FY2023 | Dec 31, 2023 | -$23.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$835.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $123.57M | +258.9% |
| Q4 FY2022 | Dec 31, 2022 | -$12.24M | -209.4% |
| Q3 FY2022 | Sep 30, 2022 | -$16.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.49M | – |
| Q1 FY2022 | Mar 31, 2022 | $34.43M | – |
| Q4 FY2021 | Dec 31, 2021 | $11.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.29M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.98M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.74M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.80M | -123.0% |
| Q4 FY2019 | Dec 31, 2019 | -$23.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.56M | – |
| Q1 FY2019 | Mar 31, 2019 | $125.16M | +157.5% |
| Q4 FY2018 | Dec 31, 2018 | -$24.35M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.65M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.50M | – |
| Q1 FY2018 | Mar 31, 2018 | $48.61M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$16.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.09M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.19M | – |
See a number that looks wrong?